Cargando…

Impairment of Retrograde Neuronal Transport in Oxaliplatin-Induced Neuropathy Demonstrated by Molecular Imaging

BACKGROUND AND PURPOSE: The purpose of our study was to utilize a molecular imaging technology based on the retrograde axonal transport mechanism (neurography), to determine if oxaliplatin-induced neurotoxicity affects retrograde axonal transport in an animal model. MATERIALS AND METHODS: Mice (n = ...

Descripción completa

Detalles Bibliográficos
Autores principales: Schellingerhout, Dawid, LeRoux, Lucia G., Hobbs, Brian P., Bredow, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447809/
https://www.ncbi.nlm.nih.gov/pubmed/23029238
http://dx.doi.org/10.1371/journal.pone.0045776
Descripción
Sumario:BACKGROUND AND PURPOSE: The purpose of our study was to utilize a molecular imaging technology based on the retrograde axonal transport mechanism (neurography), to determine if oxaliplatin-induced neurotoxicity affects retrograde axonal transport in an animal model. MATERIALS AND METHODS: Mice (n = 8/group) were injected with a cumulative dose of 30 mg/kg oxaliplatin (sufficient to induce neurotoxicity) or dextrose control injections. Intramuscular injections of Tetanus Toxin C-fragment (TTc) labeled with Alexa 790 fluorescent dye were done (15 ug/20 uL) in the left calf muscles, and in vivo fluorescent imaging performed (0–60 min) at baseline, and then weekly for 5 weeks, followed by 2-weekly imaging out to 9 weeks. Tissues were harvested for immunohistochemical analysis. RESULTS: With sham treatment, TTc transport causes fluorescent signal intensity over the thoracic spine to increase from 0 to 60 minutes after injection. On average, fluorescence signal increased 722%+/−117% (Mean+/−SD) from 0 to 60 minutes. Oxaliplatin treated animals had comparable transport at baseline (787%+/−140%), but transport rapidly decreased through the course of the study, falling to 363%+/−88%, 269%+/−96%, 191%+/−58%, 121%+/−39%, 75%+/−21% with each successive week and stabilizing around 57% (+/−15%) at 7 weeks. Statistically significant divergence occurred at approximately 3 weeks (p≤0.05, linear mixed-effects regression model). Quantitative immuno-fluorescence histology with a constant cutoff threshold showed reduced TTc in the spinal cord at 7 weeks for treated animals versus controls (5.2 Arbitrary Units +/−0.52 vs 7.1 AU +/−1.38, p<0.0004, T-test). There was no significant difference in neural cell mass between the two groups as shown with NeuN staining (10.2+/−1.21 vs 10.5 AU +/−1.53, p>0.56, T-test). CONCLUSION: We show–for the first time to our knowledge–that neurographic in vivo molecular imaging can demonstrate imaging changes in a model of oxaliplatin-induced neuropathy. Impaired retrograde neural transport is suggested to be an important part of the pathophysiology of oxaliplatin-induced neuropathy.